GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Aclarion Inc (NAS:ACON) » Definitions » EBITDA Margin %

Aclarion (Aclarion) EBITDA Margin % : -20,180.00% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Aclarion EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aclarion's EBITDA for the three months ended in Mar. 2024 was $-2.02 Mil. Aclarion's Revenue for the three months ended in Mar. 2024 was $0.01 Mil. Therefore, Aclarion's EBITDA margin for the quarter that ended in Mar. 2024 was -20,180.00%.


Aclarion EBITDA Margin % Historical Data

The historical data trend for Aclarion's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclarion EBITDA Margin % Chart

Aclarion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
-14,207.41 -8,740.82 -7,145.00 -9,028.33 -5,520.00

Aclarion Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,572.00 -8,100.00 -4,163.16 -5,928.57 -20,180.00

Competitive Comparison of Aclarion's EBITDA Margin %

For the Health Information Services subindustry, Aclarion's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclarion's EBITDA Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Aclarion's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Aclarion's EBITDA Margin % falls into.



Aclarion EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Aclarion's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-4.14/0.075
=-5,520.00 %

Aclarion's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-2.018/0.01
=-20,180.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aclarion  (NAS:ACON) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Aclarion EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Aclarion's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclarion (Aclarion) Business Description

Traded in Other Exchanges
N/A
Address
8181 Arista Place, Suite 300, Broomfield, CO, USA, 80021
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
Executives
John Paul Lorbiecki officer: Chief Financial Officer 238 CHEYENNE DRIVE, LAFAYETTE CO 80026
Brent Ness director, officer: Chief Executive Officer 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Ryan Bond officer: Chief Strategy Officer 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Stephen Deitsch director 1600 BROADWAY, SUITE 700, DENVER CO 80202
William Wesemann director 130 MONTALVO ROAD, REDWOOD CITY CA 94062
Jeffrey John Thramann director, officer: Executive Chairman 8580 STRAWBERRY LANE, NIWOT CO 80503
Michael W Dirks 10 percent owner 811 EAST 30TH AVE, HUTCHINSON KS 67502
Nuvasive Inc 10 percent owner 7475 LUSK BLVD, SAN DIEGO CA 92121
Sc Capital 1 Llc 10 percent owner 1 COMPOUND DRIVE, HUTCHINSON KS 67502
Scott Breidbart director 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404
Amanda Mae Sequira director 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
David K Neal director C/O ACLARION, INC., 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404